Phase I Trial of Novobiocin Targets Cancer with DNA Repair Gene Alterations
A phase I trial is underway to evaluate the safety and optimal dosing of novobiocin in cancer patients with DNA repair gene alterations.
Asset / Drug
Drug and asset intelligence for Novobiocin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.